Tango Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(a) Chair of the Board of Directors
Effective August 6, 2026, our Board of Directors appointed Robert Azelby as Chair of the Board of Directors.
(c) Insider Arrangements and Policies
During the fiscal quarter ended September 30, 2026, none of our directors or officers informed us of theadoption, modification ortermination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:
| Name and Title | Date Adopted | Character of Trading Arrangement (1) | Aggregate Number of Shares of Common Stock to be Purchased or Sold Pursuant to Trading Arrangement | Duration (2) | Other Material Terms | Date Terminated |
|---|---|---|---|---|---|---|
| Barbara Weber, Former Executive Chair | 7/6/2026 | Rule 10b5-1 Trading Arrangement | Up to 600,000 shares to be sold | 12/31/2026 | N/A | 10/9/2026 |
| Lesley Ann Calhoun, Director | 7/9/2026 | Rule 10b5-1 Trading Arrangement | Up to 84,000 shares to be sold | 11/1/2027 | N/A | N/A |
| John Ketchum, Director | 8/18/2026 | Rule 10b5-1 Trading Arrangement | Up to 24,937 shares to be sold | 8/31/2027 | N/A | N/A |
(1) This trading arrangement, identified as a “Rule 10b5-1 Trading Arrangement” is intended to satisfy the affirmative defense of Rule 10b5-1(c).
(2) This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table. This trading arrangement, identified as a “Rule 10b5-1 Trading Arrangement” only permits transactions upon expiration of the applicable mandatory cooling-off period under Rule 10b5-1.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.